Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)Seeking Alpha • 01/08/24
U.S. FDA Approves Label Update for Kite's Yescarta® CAR T-Cell Therapy to Include Overall Survival DataBusiness Wire • 12/21/23
Gilead Sciences and Compugen strike commercialization deal for immunotherapy programProactive Investors • 12/20/23
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy ProgramBusiness Wire • 12/19/23
Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin LymphomasBusiness Wire • 12/12/23
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite's Tecartus® in Patients With Aggressive Blood CancersBusiness Wire • 12/12/23
Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell LymphomaBusiness Wire • 12/11/23
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive YearBusiness Wire • 12/11/23
Dividend Lovers Betting Big on 6 Goldman Sachs Top Conviction List Picks for 202424/7 Wall Street • 12/09/23